Pharmacokinetics and Safety of Deuremidevir Hydrobromide (JT001) in Subjects with Mild and Moderate Renal Impairment: An Open-Label, Parallel-Group Phase I Study

Tong Lu MSc, Xi Tan MSc, Shijuan Kuang MSc, Qin Meng MSc, Ge Yu MSc, Jianjun Zou PhD, MD, Yuya Wang PhD
{"title":"Pharmacokinetics and Safety of Deuremidevir Hydrobromide (JT001) in Subjects with Mild and Moderate Renal Impairment: An Open-Label, Parallel-Group Phase I Study","authors":"Tong Lu MSc,&nbsp;Xi Tan MSc,&nbsp;Shijuan Kuang MSc,&nbsp;Qin Meng MSc,&nbsp;Ge Yu MSc,&nbsp;Jianjun Zou PhD, MD,&nbsp;Yuya Wang PhD","doi":"10.1002/jcph.70311","DOIUrl":null,"url":null,"abstract":"<p>JT001 (deuremidevir hydrobromide, VV116) is an oral antiviral prodrug that is rapidly converted in vivo to its active metabolite, 116-N1. Since 116-N1 is mainly cleared by the kidneys, renal impairment may increase its systemic exposure. This study evaluated the pharmacokinetics of 116-N1 following a single 0.3-g oral dose of JT001 in participants with mild or moderate renal impairment and matched healthy controls. Absorption was generally similar across groups, with comparable time to peak concentration. However, declining renal function increased exposure to 116-N1 and slowed its elimination. Terminal half-life increased from 5.31 to 8.13 and 11.2 h in mild and moderate impairment. Apparent oral clearance decreased from 34.3 L/h in healthy participants to 21.4 and 13.8 L/h in patients with mild and moderate renal impairment, respectively. Twenty-four participants (eight per renal function group) were enrolled. Geometric mean AUC<sub>0–t</sub> increased by 63% in participants with mild renal impairment (geometric mean ratio [GMR] 163.31%, 90% CI 135.99%–196.12%) and by 157% in those with moderate renal impairment (GMR 257.42%, 90% CI 214.35%–309.13%), whereas C<sub>max</sub> remained comparable between groups. JT001 was generally well tolerated, with no serious or grade ≥3 treatment-related adverse events. To further assess clinical relevance of these findings, the renal impairment data were incorporated into an updated population pharmacokinetic model. Simulations suggested that the approved regimen was suitable for patients with mild renal impairment, whereas a reduced regimen of 300 mg twice daily on Day 1 followed by 200 mg twice daily on Days 2–5 was recommended for patients with moderate renal impairment.</p>","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 10","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2026-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Clinical Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jcph.70311","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

JT001 (deuremidevir hydrobromide, VV116) is an oral antiviral prodrug that is rapidly converted in vivo to its active metabolite, 116-N1. Since 116-N1 is mainly cleared by the kidneys, renal impairment may increase its systemic exposure. This study evaluated the pharmacokinetics of 116-N1 following a single 0.3-g oral dose of JT001 in participants with mild or moderate renal impairment and matched healthy controls. Absorption was generally similar across groups, with comparable time to peak concentration. However, declining renal function increased exposure to 116-N1 and slowed its elimination. Terminal half-life increased from 5.31 to 8.13 and 11.2 h in mild and moderate impairment. Apparent oral clearance decreased from 34.3 L/h in healthy participants to 21.4 and 13.8 L/h in patients with mild and moderate renal impairment, respectively. Twenty-four participants (eight per renal function group) were enrolled. Geometric mean AUC0–t increased by 63% in participants with mild renal impairment (geometric mean ratio [GMR] 163.31%, 90% CI 135.99%–196.12%) and by 157% in those with moderate renal impairment (GMR 257.42%, 90% CI 214.35%–309.13%), whereas Cmax remained comparable between groups. JT001 was generally well tolerated, with no serious or grade ≥3 treatment-related adverse events. To further assess clinical relevance of these findings, the renal impairment data were incorporated into an updated population pharmacokinetic model. Simulations suggested that the approved regimen was suitable for patients with mild renal impairment, whereas a reduced regimen of 300 mg twice daily on Day 1 followed by 200 mg twice daily on Days 2–5 was recommended for patients with moderate renal impairment.

氢溴化德脲米韦(JT001)在轻度和中度肾功能损害患者中的药代动力学和安全性:一项开放标签、平行组I期研究
JT001 (deuremidevir hydrobromide, VV116)是一种口服抗病毒前药,在体内可迅速转化为其活性代谢物116-N1。由于116-N1主要由肾脏清除,肾脏损害可能增加其全身暴露。本研究评估了在轻度或中度肾功能损害的参与者和匹配的健康对照者中,单次口服0.3 g JT001后116-N1的药代动力学。各组间的吸收大体相似,达到峰值浓度的时间相当。然而,肾功能下降会增加116-N1的暴露并减缓其消除。轻度和中度损伤的终末半衰期分别从5.31 h增加到8.13 h和11.2 h。口服清除率从健康参与者的34.3 L/h下降到轻度和中度肾功能损害患者的21.4 L/h和13.8 L/h。24名参与者(每个肾功能组8名)入组。轻度肾功能损害受试者的几何平均AUC0-t增加了63%(几何平均比[GMR] 163.31%, 90% CI 135.99%-196.12%),中度肾功能损害受试者的几何平均比[GMR]增加了157% (GMR 257.42%, 90% CI 214.35%-309.13%),而Cmax在两组之间保持可比性。JT001总体耐受性良好,无严重或≥3级治疗相关不良事件。为了进一步评估这些发现的临床相关性,肾脏损害数据被纳入更新的人群药代动力学模型。模拟表明,批准的方案适用于轻度肾功能损害患者,而对于中度肾功能损害患者,建议在第1天减少300 mg每天两次,然后在第2-5天减少200 mg每天两次。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书